{"id":53,"date":"2019-10-28T14:47:13","date_gmt":"2019-10-28T14:47:13","guid":{"rendered":"https:\/\/www.octagamus.net\/octagam5\/?page_id=53"},"modified":"2022-09-19T22:04:46","modified_gmt":"2022-09-19T22:04:46","slug":"evidence","status":"publish","type":"page","link":"https:\/\/octagamusa.com\/octagam5\/evidence\/","title":{"rendered":"Evidence"},"content":{"rendered":"\n<h2>Octagam 5% provides protection against serious infection for patients with PI<sup>1-3<\/sup><\/h2>\n<ul>\n<li>In an open-label, multicenter study, 46 patients with PI received octagam 5% in individualized doses of 300-600 mg\/kg every 3 or 4 weeks for 12 months<\/li>\n<li>Primary efficacy endpoint: number of episodes of serious infections per patient per year.<\/li>\n<li>Secondary efficacy endpoint: number of other infections documented by radiograph or fever during the study period<\/li>\n<\/ul>\n<div class=\"content-column one_half\"><p><img class=\"alignnone wp-image-152\" alt=\"0.1 Serious Infections, Infographic\" width=\"250\" height=\"153\" data-src=\"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png\" srcset=\"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png 1869w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2-300x183.png 300w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2-1024x626.png 1024w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2-768x469.png 768w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2-1536x939.png 1536w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2-100x61.png 100w\" sizes=\"(max-width: 250px) 100vw, 250px\" \/><br><\/p><\/div>\n<div class=\"content-column one_half last_column\"><p><img class=\"alignnone size-full wp-image-153\" alt=\"ZERO Other Infections, Infographic\" width=\"250\" height=\"153\" data-src=\"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2.png\" srcset=\"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2.png 1869w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2-300x183.png 300w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2-1024x626.png 1024w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2-768x470.png 768w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2-1536x939.png 1536w, https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/ZERO-Other-Infections-Infographic_v2-100x61.png 100w\" sizes=\"(max-width: 250px) 100vw, 250px\" \/><\/p><\/div><div class=\"clear_column\"><\/div>\n<ul>\n<li>Serious infections are defined as pneumonia, bactermia, sepsis, osteomyelitis, septic arthritis, visceral abscesses, and bacterial or viral meningitis<\/li>\n<li>Contains a broad spectrum of IgG antibodies to protect against infections<\/li>\n<li>Serious infection rate of only 0.1\/patient\/year in pivotal trial<\/li>\n<li>IgG levels after 6 months of therapy still achieved &gt;85% of baseline<br>\n(levels after first infusion) for both 3- and 4-week administration schedules<\/li>\n<li>Mean 40.7-day IgG half-life in patients<\/li>\n<\/ul>\n\n","protected":false},"excerpt":{"rendered":"<p>Octagam 5% provides protection against serious infection for patients with PI1-3 In an open-label, multicenter study, 46 patients with PI&#8230;<\/p>\n","protected":false},"author":17,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-53","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protection Against Infection for Patients with PI | Octagam 5%<\/title>\n<meta name=\"description\" content=\"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/octagamusa.com\/octagam5\/evidence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protection Against Infection for Patients with PI | Octagam 5%\" \/>\n<meta property=\"og:description\" content=\"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/octagamusa.com\/octagam5\/evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"Octagam 5%\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-19T22:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/\",\"url\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/\",\"name\":\"Protection Against Infection for Patients with PI | Octagam 5%\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/12\\\/0.1-Serious-Infections-Infographic_v2.png\",\"datePublished\":\"2019-10-28T14:47:13+00:00\",\"dateModified\":\"2022-09-19T22:04:46+00:00\",\"description\":\"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/12\\\/0.1-Serious-Infections-Infographic_v2.png\",\"contentUrl\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/12\\\/0.1-Serious-Infections-Infographic_v2.png\",\"width\":1869,\"height\":1142,\"caption\":\"0.1 Serious Infections, Infographic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evidence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#website\",\"url\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/\",\"name\":\"Octagam 5%\",\"description\":\"Primary Humoral Immunodeficiency Diseases (PI)\",\"publisher\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#organization\",\"name\":\"Octagam (Immune Globulin Intravenous [Human] 5% Liquid Preparation)\",\"url\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630_5.jpg\",\"contentUrl\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2022\\\/05\\\/SocialShare_1200x630_5.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Octagam (Immune Globulin Intravenous [Human] 5% Liquid Preparation)\"},\"image\":{\"@id\":\"https:\\\/\\\/octagamusa.com\\\/octagam5\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protection Against Infection for Patients with PI | Octagam 5%","description":"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/octagamusa.com\/octagam5\/evidence\/","og_locale":"en_US","og_type":"article","og_title":"Protection Against Infection for Patients with PI | Octagam 5%","og_description":"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.","og_url":"https:\/\/octagamusa.com\/octagam5\/evidence\/","og_site_name":"Octagam 5%","article_modified_time":"2022-09-19T22:04:46+00:00","og_image":[{"url":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/","url":"https:\/\/octagamusa.com\/octagam5\/evidence\/","name":"Protection Against Infection for Patients with PI | Octagam 5%","isPartOf":{"@id":"https:\/\/octagamusa.com\/octagam5\/#website"},"primaryImageOfPage":{"@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/#primaryimage"},"image":{"@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png","datePublished":"2019-10-28T14:47:13+00:00","dateModified":"2022-09-19T22:04:46+00:00","description":"Learn about octagam 5% evidence and efficacy endpoints including lost daily time while providing protection against serious infection for patients with PI.","breadcrumb":{"@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/octagamusa.com\/octagam5\/evidence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/#primaryimage","url":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png","contentUrl":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2019\/12\/0.1-Serious-Infections-Infographic_v2.png","width":1869,"height":1142,"caption":"0.1 Serious Infections, Infographic"},{"@type":"BreadcrumbList","@id":"https:\/\/octagamusa.com\/octagam5\/evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/octagamusa.com\/octagam5\/"},{"@type":"ListItem","position":2,"name":"Evidence"}]},{"@type":"WebSite","@id":"https:\/\/octagamusa.com\/octagam5\/#website","url":"https:\/\/octagamusa.com\/octagam5\/","name":"Octagam 5%","description":"Primary Humoral Immunodeficiency Diseases (PI)","publisher":{"@id":"https:\/\/octagamusa.com\/octagam5\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/octagamusa.com\/octagam5\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/octagamusa.com\/octagam5\/#organization","name":"Octagam (Immune Globulin Intravenous [Human] 5% Liquid Preparation)","url":"https:\/\/octagamusa.com\/octagam5\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/octagamusa.com\/octagam5\/#\/schema\/logo\/image\/","url":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630_5.jpg","contentUrl":"https:\/\/octagamusa.com\/octagam5\/wp-content\/uploads\/sites\/2\/2022\/05\/SocialShare_1200x630_5.jpg","width":1200,"height":630,"caption":"Octagam (Immune Globulin Intravenous [Human] 5% Liquid Preparation)"},"image":{"@id":"https:\/\/octagamusa.com\/octagam5\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/pages\/53","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/comments?post=53"}],"version-history":[{"count":0,"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/pages\/53\/revisions"}],"wp:attachment":[{"href":"https:\/\/octagamusa.com\/octagam5\/wp-json\/wp\/v2\/media?parent=53"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}